Amarex and CardioDynamics Announce Strategic Alliance Agreement

A strategic alliance has been formed between Amarex Clinical Research (Germantown, MD, USA) and CardioDynamics (San Diego, CA, USA), which will enable advanced data analysis services through Amarex's secure WebView portal, a parallel-processing system in which detailed cardiovascular tables and graphs are created from real-time trial data that enable sponsors to make advanced cardiac safety assessments in their phase I-IV clinical development programs.

Amarex, a full-service clinical research organization (CRO), teamed this with noninvasive hemodynamic data outputs from CardioDynamics' proprietary BioZ Impedance Cardiography (ICG) technology and BioZport application software to provide highly-detailed and customized individual and group data displays of critical cardiac safety and performance variables. Investigators and sponsors can easily view these reports online via the WebView portal, allowing instantaneous decisions relating to dose selection, safety outcomes, and therapeutic efficacy of cardioactive agents.

"We believe that CardioDynamics' ICG technology provides the pharmaceutical industry with an important new level of hemodynamic data that will clearly enhance decision making regarding dosing, patient safety, and patient selection,” said Dr. Kazem Kazempour, president and CEO of Amarex.

Commenting on the strategic alliance, Michael K. Perry, CEO of CardioDynamics, a leading manufacturer and marketer of noninvasive ICG products and medical device electrodes, added "We are very pleased to partner with Amarex and believe that their ‘parallel processing of data' philosophy, highly-regarded reputation in the biometrics and data management field, and extensive global experience in the biopharmaceutical clinical trial arena make them an excellent strategic alliance partner.”


Related Links:
Amarex Clinical Research
CardioDynamics